<
Search this site powered by FreeFind




Digital Infrared Thermal Imaging In Medical Therapy


Digital technology now makes Digital Infrared Thermal Imaging available to all. There now is a completely safe test that can aid in diagnosis, treatment and monitoring with absolutely no risk or radiation exposure.

DITI, or digital infrared thermal imaging, is a noninvasive diagnostic test that allows a health practitioner to see and measure changes in skin surface temperature. An infrared scanning camera translates infrared radiation emitted from the skin surface and records them on a color monitor. This visual image graphically maps the body temperature and is referred to as a thermogram. The spectrum of colors indicates an increase or decrease in the amount of infrared radiation being emitted from the body surface. In healthy people, there is a symmetrical skin pattern which is consistent and reproducible for any individual.

DITI is highly sensitive and can therefore be used clinically to detect disease in the vascular, muscular, neural and skeletal systems. Medical DITI has been used extensively in human medicine in the United States, Europe and Asia for the past 20 years. Until now, bulky equipment has hindered its diagnostic and economic feasibility. Now, PC-based infrared technology designed specifically for clinical application has changed all this.

Clinical uses for DITI include, defining the extent of a lesion of which a diagnosis has previously been made (for example, vascular disease); localizing an abnormal area not previously identified, so further diagnostic tests can be performed (as in Irritable Bowel Syndrome); detecting early lesions before they are clinically evident (as in breast cancer or other breast diseases); and monitoring the healing process before a patient returns to work or training (as in workman's compensation claims).

Medical DITI is filling the gap in clinical diagnosis; X-ray, Computed Tomography, Ultrasound and Magnetic Resonance Imaging (MRI), are tests of anatomy or structure. DITI is unique in its capability to show physiological or functional changes and metabolic processes. It has also proven to be a very useful complementary procedure to other diagnostic procedures.

Unlike most diagnostic modalities DITI is non invasive. It is a very sensitive and reliable means of graphically mapping and displaying skin surface temperature. With DITI you can diagnosis, evaluate, monitor and document a large number of injuries and conditions, including soft tissue injuries and sensory/autonomic nerve fiber dysfunction. Medical DITI can offer considerable financial savings by avoiding the need for more expensive investigation for many patients. Medical DITI can graphically display the biased feeling of pain by accurately displaying the changes in skin surface temperature. Disease states commonly associated with pain include Reflex Sympathetic Dystrophy or RSD, Fibromyalgia and Rheumatoid arthritis.

Medical DITI can show a combined effect of the autonomic nervous system and the vascular system, down to capillary dysfunctions. The effects of these changes reveal an asymmetry in temperature distribution on the surface of the body. DITI is a monitor of thermal abnormalities present in a number of diseases and physical injuries. It is used as an aid for diagnosis and prognosis, as well as therapy follow up and rehabilitation monitoring, within clinical fields that include rheumatology, neurology, physiotherapy, sports medicine, oncology, pediatrics, orthopedics and many others.

Results obtained with medical DITI systems are totally objective and show excellent correlation with other diagnostic tests.

Thermographic screening is not covered by most insurance companies but is surprisingly affordable for most people. For more information or to find a certified clinic in your area, go to www.proactivehealthonline.com.

Brenda Witt is co-owner of Proactive Health Solutions in Southern California. She is an American College of Clinical Thermology (ACCT) certified thermographer in the Orange County area.


MORE RESOURCES:
Breastfeeding for at least six months might lower the risk of developing so-called "triple negative" breast cancer, an aggressive form of the disease that is more common in black and younger women, according to a study published on Monday in the journal Cancer, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 8/24).

A new promising enzyme target for a specific type of breast cancer, Brk, has been identified in research published on August 21, 2008 in the Proceedings of the National Academy of Sciences (PNAS.) In a specific subset of breast cancer patients, the tumor cells produce high levels of the protein ErbB2 (also called HER2) which pushes the cells to proliferate without limit, a characteristic common of all cancers.

The American Medical Student Association (AMSA), the nation's oldest and largest, independent association for physicians-in-training, announces the commencement of AMSA Academy, a training ground for physician leaders. Established by students, for students, AMSA Academy takes medical students through the core competencies of leadership and project implementation, while building on key principles of important topics in medicine. There are currently 22 programs offered.

Happiness and optimism may play a role against breast cancer while adverse life events can increase the risk of developing the disease, according to a study by Professor Ronit Peled, at Ben-Gurion University of the Negev in Israel. An article on the study titled "Breast Cancer, Psychological Distress and Life Events among Young Women," was just published in the British journal BMC Cancer (8:245, August 2008).

Feelings of happiness and optimism play a positive role against breast cancer. Research published in the open access journal BMC Cancer suggests that while staying positive has a protective role, adverse life events such as the loss of a parent or close relative, divorce or the loss of a spouse can increase a woman's risk of developing the disease.

New research may explain why breast cancer tends to be more aggressive in women with denser breast tissue. Breast cancer cells grown in dense, rigid surroundings step up their invasive activities, Vanderbilt-Ingram Cancer Center investigators report in the Sept. 9 issue of Current Biology. The findings suggest a cellular mechanism for the correlation between human breast tissue density and tumor aggressiveness.

Two independent research groups have found that simultaneous inhibition of two signaling pathways resulted in substantially enhanced antitumor effects in mouse models of prostate and breast cancer. In an accompany commentary, Steven Grant, at Virginia Commonwealth University Health Science Center, Richmond, discusses the clinical importance of these studies and highlights some of the questions that still need to be answered.

A new study published on bmj.com argues that for older women, health related quality of life can be improved by hormone replacement therapy (HRT). The authors recommend that HRT guidelines should be revised with this most current evidence taken into consideration. Earlier studies have shown that HRT has the potential for general improvements in quality of life measures - how patients feel or function.

Duke University chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected. The researchers also deduced that this molecule -- called largazole -- acts on cells through the same chemical mechanism as other anti-cancer compounds on the market or in clinical trials.

Seeking to improve on nature, scientists used a spice-based compound as a starting point and developed synthetic molecules that, in lab settings, are able to kill cancer cells and stop the cells from spreading. The researchers are combining organic chemistry, computer-aided design and molecular biology techniques in developing and testing pharmaceutical compounds that can fight breast and prostate cancer cells.

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that the first patient has been treated in a global Phase 3 clinical trial of IMC-1121B, its anti-vascular endothelial growth factor receptor-2 (VEGFR-2) IgG1 monoclonal antibody, in women with metastatic breast cancer.

Advocates, including those for breast cancer patients, are concerned about their relationship with pharmaceutical company Genentech following Roche's bid for the company, the

A decade-long Nebraska study that showed disparities in breast and cervical cancer screenings could have spurred changes that raised the percentage of women screened in the state. "Disparities in screening between racial and ethnic groups, even in a homogeneous state such as Nebraska, are a problem and by digging into some of the differences we were able to have an impact on breast and cervical cancer screening," said lead study author Shingairai Feresu, Ph.D.

Women who survive breast cancer for at least five years after treatment have an 89% chance that they will not have a recurrence of the cancer after 10 years and an 81% chance after 15 years, according to a study published online Tuesday in the Journal of the National Cancer Institute,

Research by scientists at the University of Sheffield suggests that the combination of zoledronic acid (a drug used to prevent bone loss) and chemotherapy agent doxorubicin could stop the growth of breast cancer tumours. Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "Breakthrough welcomes any research which investigates new uses for existing treatments to help benefit people with breast cancer.

An article published in The Lancet Oncology reports that postmenopausal women with breast cancer who are on endocrine treatment are likely to experience arthralgia and arthritis (joint symptoms) if they previously have used hormone replacement therapy (HRT), received a hormone-receptor positive tumor diagnosis, undergone chemotherapy, received treatment with anastrozole versus tamoxifen, or been obese.

Scientists in the UK and Finland have discovered that a new combination of the chemotherapy drug doxorubicin and the bone-protecting drug zoledronic acid, both of which are considerably cheaper than herceptin, stopped breast cancer tumors growing in mice. Experts suggest that since both drugs are already in use, and if the combination proves effective and safe in human clinical trials, it should not take as long for it to be available as a new treatment for patients.

Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.

Breast cancer patients and their physicians may make more informed, long-term treatment decisions using risk assessment strategies to help determine probability of recurrence, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 online issue of the Journal of the National Cancer Institute.

Famous names from the fashion, television, radio and music industries have come together to back Fashion Targets Breast Cancer® (FTBC) UK in an advertising campaign which subtly plays on the topic of celebrity charity endorsement. Natalie Imbruglia, Anna Friel, Alan Carr, Edith Bowman and Twiggy have been shot by acclaimed photographer Rankin wearing their FTBC T-shirts with pride for the campaign from leading charity Breakthrough Breast Cancer which aims to raise £1m.

US researchers estimated that the risk of relapse for breast cancer patients who were cancer-free for five years after systemic therapy (chemotherapy, hormone therapy, or both, as well as surgery) was not negligible although it was probably lower than many people realized.

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.

American Airlines, the world's largest airline, and Susan G. Komen for the Cure®, the world's largest breast cancer organization, announced an expanded partnership with the unveiling of two specially co-branded aircraft, an American Airlines Boeing 757 and an American Eagle Embraer 145, each incorporating the renowned vivid pink-ribbon motif.

Geron Corporation (Nasdaq: GERN) announced the enrollment of the first patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in locally recurrent or metastatic breast cancer. The primary objective of the Phase I/II, dose escalation study is to determine the safety, maximum tolerated dose (MTD) and objective response rate of GRN163L when administered intravenously in combination with a paclitaxel/bevacizumab regimen in this patient population.

A new discovery may lead to more effective screening and treatment for patients with a difficult to recognize syndrome characterized by tumor-like growths and a high risk of developing specific cancers. The research, published by Cell Press in the August 7 issue of the American Journal of Human Genetics, is the first in over thirteen years to identify an alternate susceptibility gene for Cowden syndrome (CS) and related disorders.

home | site map| privacy policy
© 2008, Celerity Consultants, Mumbai, India, All Rights Reserved